PEDIATRICS Vol. 97 No. 2 February 1996, pp. 246-250
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Andrich, M. P.
Right arrow Articles by Majd, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Andrich, M. P.
Right arrow Articles by Majd, M.

The Role of 131 Iodine-Metaiodobenzylguanidine Scanning in the Correlative Imaging of Patients With Neuroblastoma

Mary P. Andrich MD1, Eglal Shalaby-Rana MD1, Nasser Movassaghi MD2, and Massoud Majd MD1

1 The Department of Radiology, Children's National Medical Center, and the George Washington University, Washington, DC.
2 The Department of Hematology/Oncology, Children's National Medical Center, and the George Washington University, Washington, DC.

Objective. Metaiodobenzylguanidine (MIBG) scans were studied to determine the impact of the scan results on the clinical treatment of pediatric patients with neural crest tumors.

Methods. Serial scans were reviewed retrospectively for 27 patients with neural crest tumors: 25 with initial diagnoses of neuroblastoma (NB), 1 with ganglioneuroblastoma, and 1 with ganglioneuroma (GN). Results were compared with bone scans and computed tomography scans, as well as surgical pathologic findings.

Results. At initial diagnosis, when compared with bone and computed tomographic scans, MIBG imaging did not identify any unsuspected lesions that resulted in a change in staging. Thirteen patients with NB who had initially positive MIBG scan results had serial studies that normalized during therapy. However, after completion of therapy, 8 of 13 had relapses of the disease. Although areas of active disease were well delineated by other standard imaging modalities for all 8, only 4 (50%) had MIBG study results that were positive in sites of relapse. There were 4 cases of GN (1 at diagnosis and 3 after therapy for NB) demonstrating an uptake of MIBG that was similar in appearance to that in NB.

Conclusions. MIBG imaging did not change the staging or alter treatment during therapy for any patient. Normalization of positive study results was an unreliable indicator of outcome for children with NB. Furthermore, when relapse occurred, MIBG scans identified only 50% of those with active NB. The uptake of MIBG in GN was indistinguishable from that in NB. In this series, the results of serial MIBG studies did not have a significant impact on patient treatment.

Key Words: correlative imaging • metaiodobenzylguanidine • neuroblastoma

Submitted on August 22, 1994
Accepted on April 4, 1995




This article has been cited by other articles:


Home page
 JNMHome page
B. H. Kushner
Neuroblastoma: A Disease Requiring a Multitude of Imaging Studies
J. Nucl. Med., July 1, 2004; 45(7): 1172 - 1188.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. H. Kushner, S. D.J. Yeh, K. Kramer, S. M. Larson, and N.-K. V. Cheung
Impact of Metaiodobenzylguanidine Scintigraphy on Assessing Response of High-Risk Neuroblastoma to Dose-Intensive Induction Chemotherapy
J. Clin. Oncol., March 15, 2003; 21(6): 1082 - 1086.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
G. J. Lonergan, C. M. Schwab, E. S. Suarez, and C. L. Carlson
From the Archives of the AFIP : Neuroblastoma, Ganglioneuroblastoma, and Ganglioneuroma: Radiologic-Pathologic Correlation
RadioGraphics, July 1, 2002; 22(4): 911 - 934.
[Abstract] [Full Text] [PDF]